



Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755

Worldwide Biopharmaceuticals
January 2010

Subject: NORPACE® Controlled Release (disopyramide phosphate extended-release capsules) 100 mg and 150 mg Product Shortage RESOLVED

Dear Healthcare Provider:

Pfizer would like to inform you that NORPACE® CR 100 mg and 150 mg are once again available to your patients through normal pharmacy distribution channels.

We apologize for any inconvenience caused by the temporary product shortage of NORPACE® CR 100 mg and 150 mg. This product shortage occurred as a result of a dramatic increase in demand due to the discontinuation of a generic version of disopyramide phosphate controlled-release capsules. Please be assured that Pfizer has taken steps to increase production to meet the increased demand and avoid future product shortages.

Please continue to direct any product information questions to Pfizer Medical Information at 1-800-438-1985.

Angela Hwang
Vice President, US Established Brands
Pfizer Inc
235 East 42nd Street
New York, NY 10017

Elyse Shapiro
Senior Medical Director
Pfizer Inc
235 East 42nd Street
New York, NY 10017

Please see the enclosed full prescribing information for NORPACE® and NORPACE® CR.